82C Stock Overview
Engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
NIOX Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.79 |
| 52 Week High | UK£0.84 |
| 52 Week Low | UK£0.60 |
| Beta | 0.90 |
| 1 Month Change | 0.64% |
| 3 Month Change | 8.22% |
| 1 Year Change | 14.49% |
| 3 Year Change | 97.50% |
| 5 Year Change | 293.03% |
| Change since IPO | -77.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 82C | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 10.5% | -1.4% | -0.8% |
| 1Y | 14.5% | -3.9% | 3.2% |
Return vs Industry: 82C exceeded the German Medical Equipment industry which returned -3.9% over the past year.
Return vs Market: 82C exceeded the German Market which returned 3.2% over the past year.
Price Volatility
| 82C volatility | |
|---|---|
| 82C Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 82C has not had significant price volatility in the past 3 months.
Volatility Over Time: 82C's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 92 | n/a | investors.niox.com |
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022.
NIOX Group Plc Fundamentals Summary
| 82C fundamental statistics | |
|---|---|
| Market cap | €351.70m |
| Earnings (TTM) | €11.16m |
| Revenue (TTM) | €43.23m |
31.5x
P/E Ratio8.1x
P/S RatioIs 82C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 82C income statement (TTM) | |
|---|---|
| Revenue | UK£36.80m |
| Cost of Revenue | UK£10.30m |
| Gross Profit | UK£26.50m |
| Other Expenses | UK£17.00m |
| Earnings | UK£9.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.022 |
| Gross Margin | 72.01% |
| Net Profit Margin | 25.82% |
| Debt/Equity Ratio | 0% |
How did 82C perform over the long term?
See historical performance and comparison